ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "f5c28caa-6b32-4ef8-acb9-5129a1ec6b4c"}, "_deposit": {"id": "6025", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "6025"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00006025", "sets": ["455", "562"]}, "item_6_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "日本における進行胃がんに対するパクリタキセルとラムシルマブ併用療法の費用対効果分析"}]}, "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-03-23", "bibliographicIssueDateType": "Issued"}, "bibliographic_titles": [{}]}]}, "item_6_date_granted_51": {"attribute_name": "学位授与年月日", "attribute_value_mlt": [{"subitem_dategranted": "2018-03-23"}]}, "item_6_degree_grantor_49": {"attribute_name": "学位授与機関", "attribute_value_mlt": [{"subitem_degreegrantor": [{"subitem_degreegrantor_name": "新潟大学"}]}]}, "item_6_degree_name_48": {"attribute_name": "学位名", "attribute_value_mlt": [{"subitem_degreename": "博士(医学)"}]}, "item_6_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose: The combination of paclitaxel + ramucirumab is a standard second-line treatment in patients with advanced gastric cancer. This therapy has been associated with increased median overall survival and progression-free survival compared with those with paclitaxel monotherapy. We evaluated the cost-effectiveness of paclitaxel + ramucirumab combination therapy in patients with advanced gastric cancer, from the perspective of health care payers in Japan. Methods: We constructed a Markov model to compare, over a time horizon of 3 years, the costs and effectiveness of the combination of paclitaxel + ramucirumab and paclitaxel alone as second-line therapies for advanced gastric cancer in Japan. Health outcomes were measured in life-years (LYs) and quality-adjusted (QA) Lys gained. Costs were calculated using year- 2016 Japanese yen (¥1 = US $17.79) according to the social insurance reimbursement schedule and drug tariff of the fee-for-service system in Japan. Model robustness was addressed through 1-way and probabilistic sensitivity analyses. The costs and QALYs were discounted at a rate of 2% per year. The willingness-to-pay threshold was set at the World Health Organization\u0027s criterion of ¥12 million, because no consensus exists regarding the threshold for acceptable cost per QALY ratios in Japan\u0027s health policy. Findings: Paclitaxel + ramucirumab combination therapy was estimated to provide an additional 0.09 QALYs (0.10LYs) at a cost of ¥3,870,077, resulting in an incremental cost-effectiveness ratio of ¥43,010,248/QALY. The incremental cost-effectiveness ratio for the combination therapy was \u003e¥12 million/QALY in all of the 1-way and probabilistic sensitivity analyses. Implications: Adding ramucirumab to a regimen of paclitaxel in the second-line treatment of advanced gastric cancer is expected to provide a minimal incremental benefit at a high incremental cost per QALY. Based on our findings, adjustments in the price of ramucirumab, as well as improves in other clinical parameters such as survival time and adverse event in advanced gastric cancer therapy, are needed.", "subitem_description_type": "Abstract"}]}, "item_6_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "学位の種類: 博士(医学). 報告番号: 甲第4427号. 学位記番号: 新大院博(医)甲第826号. 学位授与年月日: 平成30年3月23日", "subitem_description_type": "Other"}, {"subitem_description": "Clinical Therapeutics. 2017. 39(12), 2380-2388.", "subitem_description_type": "Other"}]}, "item_6_description_53": {"attribute_name": "学位記番号", "attribute_value_mlt": [{"subitem_description": "新大院博(医)甲第826号", "subitem_description_type": "Other"}]}, "item_6_dissertation_number_52": {"attribute_name": "学位授与番号", "attribute_value_mlt": [{"subitem_dissertationnumber": "13101甲第4427号"}]}, "item_6_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "51274", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "齋藤, 翔太"}]}]}, "item_6_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟大学"}]}, "item_6_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "info:doi/10.1016/j.clinthera.2017.10.017", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_15": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Elsevier"}]}, "item_6_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "ETD"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Saito, Shota"}], "nameIdentifiers": [{"nameIdentifier": "51273", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-05"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "h29nmk826.pdf", "filesize": [{"value": "436.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 436600.0, "url": {"label": "本文", "url": "https://niigata-u.repo.nii.ac.jp/record/6025/files/h29nmk826.pdf"}, "version_id": "bf302891-3fdb-4ae8-93ee-1acab45aaa76"}, {"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-05"}], "displaytype": "detail", "download_preview_message": "", "file_order": 1, "filename": "h29nmk826_a.pdf", "filesize": [{"value": "1.2 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1200000.0, "url": {"label": "要旨", "url": "https://niigata-u.repo.nii.ac.jp/record/6025/files/h29nmk826_a.pdf"}, "version_id": "41352949-4ebf-47bb-87c9-51226362f272"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "cost-effectiveness", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gastric cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Markov model", "subitem_subject_scheme": "Other"}, {"subitem_subject": "paclitaxel", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ramucirumab", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "thesis", "resourceuri": "http://purl.org/coar/resource_type/c_46ec"}]}, "item_title": "Cost-Effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-Line Chemotherapy in Japan", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Cost-Effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-Line Chemotherapy in Japan"}, {"subitem_title": "Cost-Effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-Line Chemotherapy in Japan", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["455", "562"], "permalink_uri": "http://hdl.handle.net/10191/50423", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-07-26"}, "publish_date": "2018-07-26", "publish_status": "0", "recid": "6025", "relation": {}, "relation_version_is_last": true, "title": ["Cost-Effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-Line Chemotherapy in Japan"], "weko_shared_id": 2}
  1. 0 資料タイプ別
  2. 02 学位論文
  1. 250 大学院医歯学総合研究科(医)
  2. 60 博士学位論文
  3. 10 博士学位論文

Cost-Effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-Line Chemotherapy in Japan

http://hdl.handle.net/10191/50423
http://hdl.handle.net/10191/50423
ab32ac5f-c764-4ea5-9aeb-43a0b4509e6e
名前 / ファイル ライセンス アクション
h29nmk826.pdf 本文 (436.6 kB)
h29nmk826_a.pdf 要旨 (1.2 MB)
Item type 学位論文 / Thesis or Dissertation(1)
公開日 2018-07-26
タイトル
タイトル Cost-Effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-Line Chemotherapy in Japan
タイトル
言語 en
タイトル Cost-Effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-Line Chemotherapy in Japan
言語
言語 eng
キーワード
主題Scheme Other
主題 cost-effectiveness
キーワード
主題Scheme Other
主題 gastric cancer
キーワード
主題Scheme Other
主題 Markov model
キーワード
主題Scheme Other
主題 paclitaxel
キーワード
主題Scheme Other
主題 ramucirumab
資源タイプ
資源 http://purl.org/coar/resource_type/c_46ec
タイプ thesis
その他のタイトル
その他のタイトル 日本における進行胃がんに対するパクリタキセルとラムシルマブ併用療法の費用対効果分析
著者 Saito, Shota

× Saito, Shota

WEKO 51273

Saito, Shota

Search repository
著者別名
識別子 51274
識別子Scheme WEKO
姓名 齋藤, 翔太
抄録
内容記述タイプ Abstract
内容記述 Purpose: The combination of paclitaxel + ramucirumab is a standard second-line treatment in patients with advanced gastric cancer. This therapy has been associated with increased median overall survival and progression-free survival compared with those with paclitaxel monotherapy. We evaluated the cost-effectiveness of paclitaxel + ramucirumab combination therapy in patients with advanced gastric cancer, from the perspective of health care payers in Japan. Methods: We constructed a Markov model to compare, over a time horizon of 3 years, the costs and effectiveness of the combination of paclitaxel + ramucirumab and paclitaxel alone as second-line therapies for advanced gastric cancer in Japan. Health outcomes were measured in life-years (LYs) and quality-adjusted (QA) Lys gained. Costs were calculated using year- 2016 Japanese yen (¥1 = US $17.79) according to the social insurance reimbursement schedule and drug tariff of the fee-for-service system in Japan. Model robustness was addressed through 1-way and probabilistic sensitivity analyses. The costs and QALYs were discounted at a rate of 2% per year. The willingness-to-pay threshold was set at the World Health Organization's criterion of ¥12 million, because no consensus exists regarding the threshold for acceptable cost per QALY ratios in Japan's health policy. Findings: Paclitaxel + ramucirumab combination therapy was estimated to provide an additional 0.09 QALYs (0.10LYs) at a cost of ¥3,870,077, resulting in an incremental cost-effectiveness ratio of ¥43,010,248/QALY. The incremental cost-effectiveness ratio for the combination therapy was >¥12 million/QALY in all of the 1-way and probabilistic sensitivity analyses. Implications: Adding ramucirumab to a regimen of paclitaxel in the second-line treatment of advanced gastric cancer is expected to provide a minimal incremental benefit at a high incremental cost per QALY. Based on our findings, adjustments in the price of ramucirumab, as well as improves in other clinical parameters such as survival time and adverse event in advanced gastric cancer therapy, are needed.
内容記述
内容記述タイプ Other
内容記述 学位の種類: 博士(医学). 報告番号: 甲第4427号. 学位記番号: 新大院博(医)甲第826号. 学位授与年月日: 平成30年3月23日
内容記述
内容記述タイプ Other
内容記述 Clinical Therapeutics. 2017. 39(12), 2380-2388.
書誌情報 発行日 2018-03-23
出版者
出版者 新潟大学
DOI
識別子タイプ DOI
関連識別子 info:doi/10.1016/j.clinthera.2017.10.017
権利
権利情報 Elsevier
著者版フラグ
値 ETD
学位名
学位名 博士(医学)
学位授与機関
学位授与機関名 新潟大学
学位授与年月日
学位授与年月日 2018-03-23
学位授与番号
学位授与番号 13101甲第4427号
学位記番号
内容記述タイプ Other
内容記述 新大院博(医)甲第826号
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 08:40:55.814582
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3